ABT
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Abbott Laboratories
- Nom
- Abbott Laboratories
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NYSE
- Capitalisation
- $176.8B
- Employés
- 115,000
- PDG
- Robert Ford
- Site web
- https://www.abbott.com
- Marché
- BDXBSXDHREWGEHCJNJ
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$21,594,172
Avg sell (VWAP, 90d window) $115.99 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-02 | MCCOY JOHN A. JR. | Sell · S | 27 | $109.54 | $2,958 | Form 4 |
| 2026-08-25 | Ford Robert B | Sell · S | 180,297 | $116.19 | $20,948,708 | Form 4 |
| 2026-08-11 | Morrone Louis H. | Sell · S | 5,850 | $109.83 | $642,506 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-18 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
| 2026-09-04 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-07-30 | Rich McCormick | Sale | $1,001 - $15,000 |
| 2026-07-17 | Mike Kelly | Sale (Full) | $1,001 - $15,000 |
| 2026-07-14 | Rick W. Allen | Sale (Full) | $15,001 - $50,000 |
| 2026-07-08 | Richard Ray Larsen | Sale (Full) | $1,001 - $15,000 |
| 2026-06-16 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2026-06-12 | Rich McCormick | Purchase | $1,001 - $15,000 |
| 2026-06-12 | Rich McCormick | Purchase | $1,001 - $15,000 |
| 2026-06-12 | Rich McCormick | Purchase | $1,001 - $15,000 |
| 2026-06-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-05-27 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2026-05-15 | Gilbert Ray Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2026-05-12 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2026-04-16 | Rick W. Allen | Sale (Full) | $15,001 - $50,000 |
| 2026-03-24 | Laura Friedman | Exchange | $1,001 - $15,000 |
| 2026-03-19 | Rich McCormick | Purchase | $1,001 - $15,000 |
| 2026-03-04 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2026-02-10 | Gilbert Ray Cisneros | Sale | $1,001 - $15,000 |
| 2026-01-29 | Thomas Kean | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2025-12-19 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-12-18 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-12-08 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2025-12-04 | Byron Donalds | Sale (Full) | $1,001 - $15,000 |
| 2025-12-04 | Byron Donalds | Sale (Full) | $1,001 - $15,000 |
| 2025-11-18 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-11-13 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-11-05 | Rich McCormick | Purchase | $1,001 - $15,000 |
| 2025-10-30 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-10-30 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-10-30 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-10-06 | Richard Ray Larsen | Purchase | $1,001 - $15,000 |
| 2025-08-14 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-07-21 | Thomas Kean | Purchase | $1,001 - $15,000 |
| 2025-07-18 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2025-07-10 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-06-24 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-06-16 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $50,001 - $100,000 |
| 2025-04-21 | Bruce Westerman | Sale (Full) | $1,001 - $15,000 |
| 2025-03-20 | Byron Donalds | Purchase | $1,001 - $15,000 |
| 2025-03-20 | Byron Donalds | Purchase | $1,001 - $15,000 |
| 2025-03-06 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2025-03-03 | Bruce Westerman | Purchase | $1,001 - $15,000 |
| 2025-02-13 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-01-29 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-01-28 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-01-15 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2025-01-15 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2025-01-06 | Emily Randall | Sale (Full) | $1,001 - $15,000 |
| 2024-12-16 | Thomas Kean | Purchase | $1,001 - $15,000 |
| 2024-11-19 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2024-11-04 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2024-10-23 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-08-19 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-08-09 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2024-07-29 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-07-23 | Thomas Kean | Purchase | $1,001 - $15,000 |
| 2024-07-02 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2024-02-13 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2024-01-23 | Kathy E. Manning | Sale | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-12-04 | John R. Curtis | Sale (Full) | $1,001 - $15,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-13 | John R. Curtis | Purchase | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-08-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-04 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-04 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-06-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-04-28 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2023-04-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-24 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-15 | Rich McCormick | Purchase | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Sale (Partial) | $50,001 - $100,000 |
| 2023-01-06 | Richard Ray Larsen | Sale (Full) | $1,001 - $15,000 |
| 2022-12-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-05 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-11-03 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-11-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-10-20 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2019-09-27 | Rick W. Allen | Purchase | $15,001 - $50,000 |
| 2019-09-13 | Rick W. Allen | Purchase | $15,001 - $50,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
ABT presents a solid financial foundation with strong liquidity (75) and decent fundamental trends (65), but the catalyst score (55) is moderate with no insider cluster buying and mixed institutional signals, limiting…
The first sentence of the analysis written for ABT on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Supports a bullish reading. 7 purchase disclosures year to date
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.58 · operating margin 18%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 55.5% | 50.8% | 50.0% | 51.1% | 53.9% | |
| Ebit Margin | 19.9% | 18.2% | 18.4% | 19.7% | 20.0% | |
| Ebitda Margin | 26.1% | 25.8% | 26.4% | 27.2% | 28.2% | |
| Operating Profit Margin | 18.2% | 16.3% | 16.0% | 19.2% | 21.4% | |
| Pretax Profit Margin | 19.1% | 16.7% | 16.6% | 19.0% | 19.1% | |
| Continuous Operations Profit Margin | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | |
| Net Profit Margin | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | |
| Bottom Line Profit Margin | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | |
| Current Ratio | 1.576 | 1.671 | 1.638 | 1.629 | 1.850 | |
| Quick Ratio | 1.183 | 1.233 | 1.163 | 1.230 | 1.456 | |
| Solvency Ratio | 0.273 | 0.496 | 0.261 | 0.272 | 0.271 | |
| Cash Ratio | 0.517 | 0.538 | 0.498 | 0.638 | 0.748 | |
| Price To Earnings Ratio | 33.500 | 14.747 | 33.355 | 27.865 | 35.451 | |
| Price To Earnings Growth Ratio | -0.654 | 0.111 | -2.053 | -36.875 | 0.616 | |
| Forward Price To Earnings Growth Ratio | -0.654 | 0.111 | -2.053 | -36.875 | 0.616 | |
| Price To Earnings Diluted Ratio | 33.680 | 14.805 | 33.661 | 28.079 | 35.721 | |
| Price To Earnings Diluted Growth Ratio | -0.656 | 0.111 | -2.056 | -36.877 | 0.620 | |
| Price To Book Ratio | 4.199 | 4.109 | 4.944 | 5.246 | 6.978 | |
| Price To Sales Ratio | 4.938 | 4.669 | 4.759 | 4.409 | 5.800 | |
| Price To Free Cash Flow Ratio | 29.599 | 30.841 | 37.729 | 24.662 | 28.887 | |
| Price To Operating Cash Flow Ratio | 22.881 | 22.888 | 26.287 | 20.088 | 23.717 | |
| Debt To Assets Ratio | 0.174 | 0.188 | 0.217 | 0.241 | 0.256 | |
| Debt To Equity Ratio | 0.289 | 0.320 | 0.411 | 0.489 | 0.538 | |
| Debt To Capital Ratio | 0.224 | 0.243 | 0.291 | 0.328 | 0.350 | |
| Long Term Debt To Capital Ratio | 0.172 | 0.209 | 0.261 | 0.284 | 0.326 | |
| Financial Leverage Ratio | 1.663 | 1.708 | 1.897 | 2.029 | 2.100 | |
| Working Capital Turnover Ratio | 4.666 | 4.578 | 4.321 | 4.184 | 4.380 | |
| Operating Cash Flow Ratio | 0.580 | 0.605 | 0.525 | 0.619 | 0.804 | |
| Operating Cash Flow Sales Ratio | 0.216 | 0.204 | 0.181 | 0.219 | 0.245 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.773 | 0.742 | 0.697 | 0.815 | 0.821 | |
| Debt Service Coverage Ratio | 2.633 | 7.307 | 4.777 | 3.761 | 7.820 | |
| Interest Coverage Ratio | 23.601 | 11.318 | 9.219 | 26.546 | 22.439 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.891 | 4.879 | 5.480 | 3.862 | 10.544 | |
| Operating Cash Flow Coverage Ratio | 0.635 | 0.560 | 0.457 | 0.534 | 0.547 | |
| Capital Expenditure Coverage Ratio | 4.406 | 3.878 | 3.297 | 5.392 | 5.588 | |
| Dividend Paid And Capex Coverage Ratio | 1.522 | 1.416 | 1.261 | 1.884 | 2.071 | |
| Dividend Payout Ratio | 0.631 | 0.286 | 0.621 | 0.477 | 0.453 | |
| Enterprise Value Multiple | 19.512 | 18.786 | 18.845 | 16.868 | 21.323 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 55.5% | ▲4.7% | ▲3.2% |
| Ebit Margin | 19.9% | ▲1.7% | ▲0.6% |
| Ebitda Margin | 26.1% | ▲0.2% | ▼-0.7% |
| Operating Profit Margin | 18.2% | ▲1.9% | ▼-0.0% |
| Pretax Profit Margin | 19.1% | ▲2.4% | ▲1.0% |
| Continuous Operations Profit Margin | 14.7% | ▼-17.2% | ▼-3.9% |
| Net Profit Margin | 14.7% | ▼-17.2% | ▼-3.9% |
| Bottom Line Profit Margin | 14.7% | ▼-17.2% | ▼-3.9% |
| Current Ratio | 1.576 | ▼-0.095 | ▼-0.097 |
| Quick Ratio | 1.183 | ▼-0.051 | ▼-0.070 |
| Solvency Ratio | 0.273 | ▼-0.223 | ▼-0.041 |
| Cash Ratio | 0.517 | ▼-0.021 | ▼-0.071 |
| Price To Earnings Ratio | 33.500 | ▲18.753 | ▲4.516 |
| Price To Earnings Growth Ratio | -0.654 | ▼-0.765 | ▲7.117 |
| Forward Price To Earnings Growth Ratio | -0.654 | ▼-0.765 | ▲7.117 |
| Price To Earnings Diluted Ratio | 33.680 | ▲18.875 | ▲4.491 |
| Price To Earnings Diluted Growth Ratio | -0.656 | ▼-0.767 | ▲7.115 |
| Price To Book Ratio | 4.199 | ▲0.089 | ▼-0.896 |
| Price To Sales Ratio | 4.938 | ▲0.269 | ▲0.023 |
| Price To Free Cash Flow Ratio | 29.599 | ▼-1.243 | ▼-0.745 |
| Price To Operating Cash Flow Ratio | 22.881 | ▼-0.006 | ▼-0.291 |
| Debt To Assets Ratio | 0.174 | ▼-0.014 | ▼-0.041 |
| Debt To Equity Ratio | 0.289 | ▼-0.031 | ▼-0.120 |
| Debt To Capital Ratio | 0.224 | ▼-0.018 | ▼-0.063 |
| Long Term Debt To Capital Ratio | 0.172 | ▼-0.037 | ▼-0.078 |
| Financial Leverage Ratio | 1.663 | ▼-0.045 | ▼-0.216 |
| Working Capital Turnover Ratio | 4.666 | ▲0.089 | ▲0.241 |
| Operating Cash Flow Ratio | 0.580 | ▼-0.025 | ▼-0.046 |
| Operating Cash Flow Sales Ratio | 0.216 | ▲0.012 | ▲0.003 |
| Free Cash Flow Operating Cash Flow Ratio | 0.773 | ▲0.031 | ▲0.004 |
| Debt Service Coverage Ratio | 2.633 | ▼-4.674 | ▼-2.627 |
| Interest Coverage Ratio | 23.601 | ▲12.283 | ▲4.976 |
| Short Term Operating Cash Flow Coverage Ratio | 2.891 | ▼-1.988 | ▼-2.640 |
| Operating Cash Flow Coverage Ratio | 0.635 | ▲0.075 | ▲0.088 |
| Capital Expenditure Coverage Ratio | 4.406 | ▲0.529 | ▼-0.106 |
| Dividend Paid And Capex Coverage Ratio | 1.522 | ▲0.105 | ▼-0.109 |
| Dividend Payout Ratio | 0.631 | ▲0.345 | ▲0.137 |
| Enterprise Value Multiple | 19.512 | ▲0.726 | ▲0.446 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $218.88B | $195.87B | $190.87B | $192.46B | $249.81B | |
| Enterprise value | $225.43B | $203.53B | $199.85B | $200.53B | $259.27B | |
| EV / Sales | 5.08x | 4.85x | 4.98x | 4.59x | 6.02x | |
| EV / Op. cash flow | 23.57x | 23.78x | 27.52x | 20.93x | 24.61x | |
| EV / Free cash flow | 30.48x | 32.05x | 39.50x | 25.70x | 29.98x | |
| EV / EBITDA | 19.51x | 18.79x | 18.84x | 16.87x | 21.32x | |
| Net debt / EBITDA | 0.57x | 0.71x | 0.85x | 0.68x | 0.78x | |
| Current ratio | 1.58x | 1.67x | 1.64x | 1.63x | 1.85x | |
| Income quality | 1.47x | 0.64x | 1.27x | 1.38x | 1.49x | |
| Graham number | $50 | $69 | $41 | $43 | $43 | |
| Graham net-net | -$9 | -$10 | -$11 | -$11 | -$12 | |
| Tax burden | 77.1% | 191.1% | 85.9% | 83.5% | 86.1% | |
| Interest burden | 96.1% | 92.1% | 90.5% | 96.3% | 95.2% | |
| Working capital | $9.50B | $9.50B | $8.83B | $9.73B | $11.13B | |
| Invested capital | $52.00B | $50.99B | $52.60B | $53.27B | $57.22B | |
| Return on assets | 7.5% | 16.5% | 7.8% | 9.3% | 9.4% | |
| Operating ROA | 9.6% | 8.8% | 8.7% | 11.2% | 12.5% | |
| Return on tangible assets | 11.4% | 25.9% | 14.1% | 16.8% | 18.0% | |
| Return on equity | 12.5% | 28.1% | 14.8% | 18.9% | 19.8% | |
| Return on invested capital | 8.4% | 9.9% | 9.1% | 11.4% | 12.6% | |
| Return on capital employed | 11.5% | 10.1% | 10.8% | 14.2% | 14.8% | |
| Earnings yield | 3.0% | 6.8% | 3.0% | 3.6% | 2.8% | |
| Free cash flow yield | 3.4% | 3.2% | 2.7% | 4.1% | 3.5% | |
| Capex / Op. cash flow | 22.7% | 25.8% | 30.3% | 18.5% | 17.9% | |
| Capex / Depreciation | 69.7% | 68.6% | 67.9% | 54.4% | 53.3% | |
| Capex / Sales | 4.9% | 5.3% | 5.5% | 4.1% | 4.4% | |
| SG&A / Sales | 27.9% | 27.8% | 27.1% | 25.4% | 26.2% | |
| R&D / Sales | 6.7% | 6.7% | 6.8% | 6.5% | 6.4% | |
| Stock comp / Sales | 1.5% | 1.6% | 1.6% | 1.6% | 1.5% | |
| Intangibles / Total assets | 34.1% | 36.5% | 44.4% | 44.7% | 47.8% | |
| Days sales outstanding | 65d | 60d | 60d | 52d | 55d | |
| Days payables outstanding | 78d | 74d | 78d | 79d | 81d | |
| Operating cycle | 185d | 170d | 179d | 158d | 150d | |
| Cash conversion cycle | 107d | 96d | 101d | 79d | 69d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-05 Park National Corp OH Sells 10,269 Shares of Abbott Laboratories $ABT Park National Corp OH lessened its position in shares of Abbott Laboratories (NYSE: ABT) by 6.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,913 shares of the healthcare product maker''s stock after selling 10,269 shares during
- 2026-10-05 Eastern Bank Decreases Stake in Abbott Laboratories $ABT Eastern Bank trimmed its position in Abbott Laboratories (NYSE: ABT) by 14.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 56,544 shares of the healthcare product maker''s stock after selling 9,287 shares during the period. Eastern Bank''s holdings in Abbott Laboratories were worth $5,588,000 as
- 2026-10-05 Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can signal worsening heart failure weeks before patients experience symptoms New capabilities help patients take a more active role in their care and stay connected to their care teams between doctor visits ABBOTT PARK, Ill., Oct. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App.
- 2026-10-02 DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.
- 2026-10-02 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
- 2026-10-02 Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- 2026-10-02 Here Are Friday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Cerebras Systems, Coinbase Global, Edison International, Northrop Grumman, Pershing Square, Robinhood Markets, and More Stocks clawed back from a wild Thursday session, oil surged past $100, and Wall Street analysts reshuffled their bets on names from Airbnb to Northrop Grumman. Find out which stocks got upgraded, downgraded, or newly covered heading into the first Friday of Q4 2026.
- 2026-10-01 These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here''s Why They Are Better Buys Anyway. Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can''t: growth in both the payout and the stock.
- 2026-10-01 Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? Abbott Laboratories offers a highly diversified revenue stream across medical devices, diagnostics, and nutrition. Intuitive Surgical maintains a dominant lead in robotic-assisted surgery with high recurring revenue from instruments and services.
- 2026-10-01 In 1935, An Illinois Secretary Bought 3 Shares Of Her Company’s Stock For $180. She Never Sold A Single Share And Always Reinvested Dividends. By The Time She Died In 2010 Her 3 Abbott Shares Had Turned Into $7.2 Million. A secretary at an Illinois pharmaceutical company made a single, unremarkable stock purchase in 1935 and then did almost nothing for the next 75 years. What her college discovered when she died would quietly rewrite everything anyone thought they knew about her.